MARKET

AUPH

AUPH

Aurinia Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.90
-0.65
-4.18%
After Hours: 14.91 +0.01 +0.07% 16:35 09/21 EDT
OPEN
15.40
PREV CLOSE
15.55
HIGH
15.40
LOW
14.66
VOLUME
1.33M
TURNOVER
--
52 WEEK HIGH
21.93
52 WEEK LOW
3.520
MARKET CAP
1.88B
P/E (TTM)
-10.6688
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hedge Funds Cant Stop Buying Aurinia Pharmaceuticals Inc (AUPH)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually
Insider Monkey · 5d ago
Aurinia Pharmaceuticals to Present at Three Upcoming Virtual Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the senior management team will participate in fireside chats during the following upcoming virtual investor conferences:
Business Wire · 09/10 11:05
Potential Positive Readout Of Aurinia Pharmaceuticals' Phase 2/3 AUDREY Trial Could Bring Best-In-Class Eye Drops For Dry Eye Syndrome
Voclosporin has proven to be a safer and much more effective derivative of cyclosporin, whose emulsion eye drop formulation was approved by FDA in 2003 to treat DES.Its Phase 2a trial has demonstrated a significant advantage of tear production versus cyclosporine as indicated in Schirmer Tear Test (STT).Aurinia's Phase 2/3 AUDREY trial is highly likely to succeed.
Seekingalpha · 09/08 13:16
Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company’s Compensation Committee granted 105 new employees non-qualified
Business Wire · 09/04 23:04
Aurinia Pharmaceuticals Q2 EPS $(0.26) Misses $(0.14) Estimate, Sales $29.00K Miss $40.00K Estimate
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.14) by 85.71 percent. This is a 52.94 percent decrease over losses of $(0.17) per
Benzinga · 08/11 20:16
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/04 16:30
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10
Business Wire · 08/04 10:05
Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets close. Aurinia’s executive team will host a conference call to
Business Wire · 07/30 10:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AUPH stock price target is 25.10 with a high estimate of 34.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 163
Institutional Holdings: 62.98M
% Owned: 49.97%
Shares Outstanding: 126.04M
TypeInstitutionsShares
Increased
45
5.22M
New
51
642.82K
Decreased
30
7.61M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Independent Director
George Milne
President/Chief Executive Officer/Director
Peter Greenleaf
Chief Financial Officer
Dennis Bourgeault
Chief Operating Officer
Michael Martin
Executive Vice President
Maxwell Donley
Executive Vice President
Robert Huizinga
Senior Vice President/Chief Compliance Officer/General Counsel
Erik Eglite
Senior Vice President/IR Contact Officer
Glenn Schulman
Chief Marketing Officer
Neil Solomons
Vice President/Director of Sales
Fran Lynch
Vice President/Director of Marketing
Chris Hays
Vice President
Cara Felish
Vice President
Tim Hermes
Other
Max Colao
Director
Daniel Billen
Director
R. Hector MacKay-Dunn
Independent Director
Joseph Hagan
Independent Director
Michael Hayden
Independent Director
David Jayne
Independent Director
Jill Leversage
Independent Director
Timothy Walbert
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average AUPH stock price target is 25.10 with a high estimate of 34.00 and a low estimate of 20.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AUPH
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. It is developing voclosporin in multiple indications. Voclosporin is an investigational therapy. It is developing voclosporin for the treatment of lupus nephritis (LN) and other proteinuric diseases. It is also advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Voclosporin is a calcineurin inhibitor (CNI). By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses and stabilizes the podocyte in the kidney.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aurinia Pharmaceuticals Inc stock information, including NASDAQ:AUPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AUPH stock methods without spending real money on the virtual paper trading platform.